Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Institutes of Health (1DP51DP5OD024576-01)
National Cancer Institute (P30 CA014520)
- License Information
-
More Information
Article History
Received: 21 December 2020
Accepted: 21 May 2021
First Online: 3 June 2021
Declarations
:
: ZSM is a member of the scientific advisory board for Archeus Technologies and Seneca Therapeutics and has received equity options for these companies. ZSM is an inventor on patents or filed patents managed by the Wisconsin Alumni Research Foundation relating to the interaction of targeted radionuclide therapies and immunotherapies, nanoparticles designed to augment the anti-tumor immune response following radiation therapy, and the development of a brachytherapy catheter capable of delivering intra-tumor injectables.
